Rubius Therapeutics (Rubius Therapeutics) Minority Interest : $0.00 Mil (As of Dec. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Rubius Therapeutics Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Rubius Therapeutics's minority interest for the quarter that ended in Dec. 2022 was $0.00 Mil.

Rubius Therapeutics Minority Interest Historical Data

The historical data trend for Rubius Therapeutics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rubius Therapeutics Minority Interest Chart

Rubius Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Minority Interest

Get a 7-Day Free Trial

Rubius Therapeutics Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Minority Interest	Get a 7-Day Free Trial															-	-	-	-	-

Rubius Therapeutics Minority Interest Calculation

Rubius Therapeutics (Rubius Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rubius Therapeutics Inc (OTCPK:RUBY) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

124 Washington Street, Suite 101, Foxborough, MA, USA, 02035

Website

https://www.rubiustx.com

Rubius Therapeutics Inc develops red cell therapeutics (RCTs) for the treatment of patients with rare diseases, cancer, and autoimmune diseases.

Executives

Dannielle Appelhans	officer: CEO and President	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Pablo J Cagnoni	director, officer: Chief Executive Officer	ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Laurence A. Turka	officer: Chief Scientific Officer	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE MA 02139
Susanne Schaffert	director	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
David R Epstein	director	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Maiken Keson-brookes	officer: CLO & Corp. Secretary	35 OAK HILL ROAD, FAYVILLE MA 01745
Flagship Ventures Fund V, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I, L.p.	10 percent owner	ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund V General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Jose Carmona	officer: Chief Financial Officer	C/O INNOCOLL HOLDINGS PLC, 3803 WEST CHESTER PIKE, NEWTOWN SQUARE PA 19073
Christina M. Coughlin	officer: Chief Medical Officer	C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY ST., SUITE 300, CAMBRIDGE MA 02139